Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Sep 24;1(1):37-40.
doi: 10.1016/j.jaccao.2019.08.010. eCollection 2019 Sep.

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors

Rhian M Touyz  1 , Ninian N Lang  1
Affiliations
Editorial

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors

Rhian M Touyz et al. JACC CardioOncol. .
No abstract available

Keywords: VEGF inhibitors; antihypertensive drugs; blood pressure; cancer; renin angiotensin aldosterone; tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
VEGFI Beneficial and Harmful Effects Leading to Improved Cancer Survival With Increased Cardiovascular Toxicities, Particularly Hypertension Ideal management of patients should balance antiangiogenic and cardiovascular toxicities so that anticancer treatment is optimized in the absence of hypertension and cardiovascular disease. BP = blood pressure; CVD = cardiovascular disease; Rx = prescription; VEGFI = vascular endothelial growth factor inhibitor.
See this image and copyright information in PMC

Comment on

References

    1. Pal S., Gong J., Mhatre S.K. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer. 2019;19:548. - PMC - PubMed
    1. Michaelson M.D., Gupta S., Agarwal N. A phase Ib study of axitinib in combination with crizotinib in patients with metastatic renal cell cancer or other advanced solid tumors. Oncologist. 2019 Jun 6 [E-pub ahead of print] - PMC - PubMed
    1. Li J., Xu J., Chen Y., Zhang J., Cao Y., Lu P. Efficacy comparison of intravitreal anti-VEGF therapy for three subtypes of neovascular age-related macular degeneration: a systematic review and meta-analysis. J Ophthalmol. 2018;2018:1425707. - PMC - PubMed
    1. Malecic N., Young H.S. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis. Expert Opin Investig Drugs. 2016;25:455–462. - PubMed
    1. Robinson E.S., Matulonis U.A., Ivy P. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5:477–483. - PMC - PubMed

LinkOut - more resources